Mikrobiomik celebrates the first Investor's Day: presents clinical and corporate progress
El pasado 24 de octubre, Mikrobiomik celebró su primer Investor´s Day, reuniendo a profesionales del sector farmacéutico y biotecnológico, socios e inversores. En la jornada se compartieron logros actuales y metas futuras de la compañía.
On 24 October, Mikrobiomik organised its first Investor's Day at the Hotel NH Collection Villa de Bilbao, bringing together professionals from the pharmaceutical and biotechnology sector, partners and investors. During the event, current achievements and future plans of the company were shared.
In the clinical segment, Dr. Rosa del Campo opened the event with a presentation on the upcoming challenges in the study of the microbiota. Then, Dr Elena Bereciartua presented promising results from the ICD-01 clinical trial to treat Clostridioides Difficile infections. A particular moment of highlight was the testimony of Axel Sommer, who shared the experience of his father's recovery thanks to the provision of the investigational drug MKB-01, offered completely free of charge through the compassionate use programme. Dr Maria Varela from La Paz Hospital presented the case of another patient successfully treated with MKB-01, who eradicated recurrent episodes of diahrrea in just 48 hours.
The second section, led by CEO Dr. Juan Basterra, reviewed the progress made since Mikrobiomik Foundation in 2018. He also announced the AEMPS' recent approval of a Phase II clinical trial in patients with recurrent diverticulitis, in collaboration with the Ramón y Cajal Institute for Health Research (IRYCIS). Dr. Patricia del Río, Director of Business Development, presented the powerful reasons to trust and invest in Mikrobiomik, which is seeking to raise 5 million euros to build a new production plant, advance in clinical trials and hire new talent. Caixa Bank, through Antonio San Segundo, explained the terms of this series A investment round.
The day concluded with institutional interventions of Marta Martinez from Cebek (Business Confederation of Bizkaia), Olatz Goitia, General Manager of Beaz, and Oscar Ugarte, General Director of Seed Capital Bizkaia, which have supported Mikrobiomik in its development since its beginnings. This event established a milestone on the company's path towards becoming a European benchmark in microbiota research.